<DOC>
	<DOCNO>NCT02099240</DOCNO>
	<brief_summary>Based current literature , investigator hypothesize patient osteomyelitis treated standard approach intravenous antibiotic full duration therapy clinical outcome patient treat experimental approach intravenous antibiotic early switch oral antibiotic . The primary objective study compare patient osteomyelitis treated standard approach intravenous antibiotic full duration therapy versus patient treat intravenous antibiotic early switch oral antibiotic relation clinical outcome 12 month discontinuation antibiotic therapy . Secondary objective study include evaluation adverse event relate use antibiotic well cost care evaluate hospital perspective .</brief_summary>
	<brief_title>Patients Response Early Switch To Oral : Osteomyelitis Study</brief_title>
	<detailed_description>1.1 . Background Information Osteomyelitis common disease associate significant morbidity high cost ( 1 ) . The treatment osteomyelitis challenge require prolonged administration antibiotic extensive surgical procedure . Even infection treat , relapse rate high 20 % ( 2 ) . When bone infect , local multiplication bacteria produce local inflammatory response presence neutrophil macrophages area microthrombi avascular necrosis . If significant area avascular necrosis develop , segment bone without blood supply become separated form sequestrum . Since infection sequestrum occur patient osteomyelitis , consider addition antibiotic treatment , patient require surgical intervention removal necrotic bone . 1.2 . Scientific Rationale There agreement regard minimal duration antibiotic therapy patient osteomyelitis . Since infect bone may take 3 4 week -- ‐ vascularize , duration therapy minimum 4 6 week antibiotic . Because different organism cause osteomyelitis , initial antibiotic therapy hospitalization include broad -- ‐spectrum antibiotic cover likely organism . As part initial management , bone biopsy regularly perform identify particular etiologic agent . Once organism antimicrobial susceptibility know , spectrum antibiotic therapy narrow , antimicrobial therapy continue antibiotic target accord susceptibility identify pathogen . Targeted antibiotic therapy patient osteomyelitis usually perform 3 5 day broad spectrum antibiotic , since time require microbiology department generate antimicrobial susceptibility bone biopsy perform . In regard route antibiotic administration , standard approach use intravenous antibiotic . 1.3 . Potential Risks A potential risk use early switch oral antibiotic patient osteomyelitis blood level achieve oral antibiotic may high enough attain clinical resolution infection . 1.4 . Potential Benefits There several potential benefit use oral antibiotic instead intravenous antibiotic . First , avoid peripherally insert central line eliminates risk line infection line -- ‐associated deep vein thrombosis . An early switch oral antibiotic may also facilitate early hospital discharge . A short hospital stay decrease risk hospital -- ‐associated complication hospital -- ‐acquired infection . Further , patient ' quality life may better without central line . Finally , total cost therapy significantly reduce oral therapy . 2 . Methods 2.1 . Trial design &amp; set This prospective , randomize , unblinded clinical trial define clinical outcome patient osteomyelitis treat experimental approach intravenous antibiotic early switch oral therapy non -- ‐inferior current standard approach intravenous antibiotic full duration therapy . 2.8 . Sample Size &amp; Statistical Analysis The null hypothesis study follow : H0 : πs -- ‐ πe ≤ -- ‐Δ Where πs proportion clinical failure intravenous therapy group , πe proportion clinical failure intravenous therapy plus early switch oral therapy group , Δ non -- ‐inferiority margin . The alternative hypothesis : HA : πs -- ‐ πe &gt; -- ‐Δ We expect 20 % clinical failure rate primary outcome intravenous antibiotic therapy group intravenous antibiotic therapy plus early switch oral antibiotic therapy group . The study power 80 % Δ 0.1 . A total 396 patient need obtain 95 % confidence interval difference failure rate two group low limit -- ‐Δ . If low limit 95 % confidence interval 10 difference clinical failure rate two arm -Δ , non -- ‐inferiority meet . Considering approximately 15 % patient lose study follow -- ‐up , total 456 patient enroll trial obtain 396 patient necessary final analysis . 3 . Data Quality Management Plan 3.1 . Overview Clinical Translational Research Support Center The University Louisville Clinical Translational Research Support Center ( CTRSC ) responsible data collection , data quality , data analysis project . The CTRSC ( http : //www.ctrsc.net ) multi -- ‐disciplinary team comprise professional medicine , public health , statistic , computer science . The team considerable experience manage support single -- ‐site multi -- ‐center clinical research study . Specifically , member CTRSC responsible : - Study design - Development data collection form - Development study manual 11 - Development electronic Internet base data entry system - Providing instruction use form data entry system - Development study database - Tracking subject enrollment - Overseeing data transmission - Providing data management - Handling data validation - Protecting confidentiality data - Performing feasibility evaluation The data quality team leader project Dr. Robert Kelley assistance Dr. Timothy Wiemken Dr. Paula Peyrani . The CTRSC access University Louisville 's high -- ‐performance computing cluster , consist 312 IBM iDatplex node two Intel Xeon quad -- ‐ core processor 2496 total core . The cluster equip variety statistical bioinformatics software include SAS , R , Matlab , ClustalW , Blast , C , Fortran , Perl , Python libraries . In addition , CTRSC several iMac IBM -- ‐compatible workstation several data management analysis package instal include R , Matlab , SQL Server 2012 , SAS , SPSS , Eclipse , Visual Studio .NET 2010 , MySQL Server 5.1 , Tableau 8.0 , REDCap . 3.2 . Purpose Data Quality Management Plan The purpose data quality management plan outline procedure process necessary : 1 . Ensure data collection data management study conduct manner consistent University Louisville standard well state federal regulation . 2 . Ensure data collect accurate complete verify source document . 3 . Provide approach early interception correction error data collection . 4 . Identify area specific education training effort regard data collection need focus . 5 . Outline tool use monitor ass data quality . 6 . Outline Data Quality Management Team meeting schedule project . 3.3 . Data Capture Primary data collection perform qualified study coordinator ( ) abstract subject data electronic medical record onto paper case report form . Once paper case report form complete , study coordinator designee enter data secure , web -- ‐based clinical data management system .</detailed_description>
	<mesh_term>Osteomyelitis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Penicillin G</mesh_term>
	<mesh_term>Penicillin G Benzathine</mesh_term>
	<mesh_term>Penicillin G Procaine</mesh_term>
	<mesh_term>Mupirocin</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Streptomycin</mesh_term>
	<mesh_term>Cefdinir</mesh_term>
	<mesh_term>Oxacillin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Cefoxitin</mesh_term>
	<mesh_term>Cefotaxime</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<mesh_term>Penicillins</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<mesh_term>Gatifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Neomycin</mesh_term>
	<mesh_term>Polymyxin B</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<mesh_term>Polymyxins</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Bacampicillin</mesh_term>
	<mesh_term>Carbenicillin</mesh_term>
	<mesh_term>Carbenicillin indanyl</mesh_term>
	<mesh_term>Mezlocillin</mesh_term>
	<mesh_term>Benzathine benzylpenicillin , procaine benzylpenicillin , drug combination</mesh_term>
	<mesh_term>Ticarcillin-clavulanic acid</mesh_term>
	<mesh_term>Ticarcillin</mesh_term>
	<mesh_term>Cefonicid</mesh_term>
	<mesh_term>Loracarbef</mesh_term>
	<mesh_term>Cefpodoxime proxetil</mesh_term>
	<mesh_term>Cefpodoxime</mesh_term>
	<mesh_term>Grepafloxacin</mesh_term>
	<mesh_term>Nalidixic Acid</mesh_term>
	<mesh_term>Sparfloxacin</mesh_term>
	<mesh_term>Netilmicin</mesh_term>
	<mesh_term>Methacycline</mesh_term>
	<mesh_term>Oxytetracycline</mesh_term>
	<mesh_term>Chlortetracycline</mesh_term>
	<mesh_term>Dalfopristin</mesh_term>
	<mesh_term>Chloramphenicol</mesh_term>
	<mesh_term>Novobiocin</mesh_term>
	<mesh_term>Spectinomycin</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<mesh_term>Lincomycin</mesh_term>
	<mesh_term>Cefuroxime axetil</mesh_term>
	<mesh_term>Cefoperazone</mesh_term>
	<mesh_term>Demeclocycline</mesh_term>
	<mesh_term>Kanamycin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Enoxacin</mesh_term>
	<mesh_term>Cefaclor</mesh_term>
	<mesh_term>Cefixime</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<mesh_term>Lomefloxacin</mesh_term>
	<mesh_term>Quinupristin-dalfopristin</mesh_term>
	<mesh_term>Cefotetan</mesh_term>
	<mesh_term>Cefuroxime</mesh_term>
	<mesh_term>Ceftizoxime</mesh_term>
	<mesh_term>Ceftibuten</mesh_term>
	<mesh_term>Cefepime</mesh_term>
	<mesh_term>Chloramphenicol succinate</mesh_term>
	<mesh_term>Ethionamide</mesh_term>
	<mesh_term>Dicloxacillin</mesh_term>
	<mesh_term>Sultamicillin</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<mesh_term>Dirithromycin</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Penicillin V</mesh_term>
	<mesh_term>Capreomycin</mesh_term>
	<mesh_term>Cefprozil</mesh_term>
	<mesh_term>Nafcillin</mesh_term>
	<mesh_term>Bacitracin</mesh_term>
	<mesh_term>Cloxacillin</mesh_term>
	<mesh_term>Norfloxacin</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Sulperazone</mesh_term>
	<mesh_term>Methenamine hippurate</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Nitrofurantoin</mesh_term>
	<mesh_term>Sulfadiazine</mesh_term>
	<mesh_term>Sulfamethizole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Nitrofurazone</mesh_term>
	<mesh_term>Sulfisoxazole</mesh_term>
	<mesh_term>Cinoxacin</mesh_term>
	<mesh_term>Methenamine</mesh_term>
	<mesh_term>Mafenide</mesh_term>
	<mesh_term>Silver Sulfadiazine</mesh_term>
	<mesh_term>Sulfacetamide</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<mesh_term>Cilastatin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Procaine</mesh_term>
	<criteria>Only adult patient invited participate trial ( age ≥ 18 year ) . A patient consider candidate participate trial follow two inclusion criterion present : 1 . Isolation organism bone culture susceptible intravenous oral antibiotic . 2 . Plus least one following : Evidence local inflammatory response , manifest local pain , edema , erythema , warmth , drainage . Evidence systemic inflammatory response , manifest fever , elevate C‐reactive protein ( CRP ) level , erythrocyte sedimentation rate ( ESR ) , white blood cell count . *Osteomyelitis‐compatible finding plain radiograph , compute tomography , bone scan , magnetic resonance imaging , positron emission tomography . Pathology report indicative osteomyelitis . A patient consider candidate participate study study team expect subject non‐compliant study follow‐up clinic visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteomyelitis</keyword>
	<keyword>IV Antibiotics</keyword>
	<keyword>Oral Antibiotics</keyword>
</DOC>